Although no aberrations of Rac2 have been directly linked to oncogenesis, Rac2 is emerging as a therapeutic target, as abrogation of Rac2 signaling slows the growth of AML and CML tumors (reviewed in ref. 31). Here, RAC2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.